New hybrid nanoparticles offer precise cell targeting

A research team drawn from the National Institute of Standards and Technology, the University of Maryland and the FDA has developed a method to combine two substances into a hybrid nanoscale particle capable of precise drug payload delivery through a target cell's membrane.

To get the hybrid particle the team combined a phospholipid membrane "bubble" called a liposome and particles of hydrogel, a water-filled network of polymer chains. The hybrid combines the targeting abilities of liposomes with the durability of the hydrogel, overcoming a tendency to rupture without the hydrogel's tendency to clump together.

The liposome-hydrogel hybrid vesicles are irradiated, adding strength to the delivery particles, which can be loaded with a therapeutic payload during the manufacturing process.

- check out the report from Science Daily

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.